title: Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).
abstract: BACKGROUND
  Depression and chronic heart failure (CHF) are common conditions, both of which are clinically and economically highly relevant. Major depression affects 20-40% of CHF patients and predicts adverse outcomes in terms of quality of life, morbidity and mortality as well as health care expenditure, independent of other factors of prognostic relevance.
  
  
  OBJECTIVE
  The purpose of the MOOD-HF trial is to clarify whether antidepressant pharmacotherapy improves outcome in CHF patients, and if so by which mechanism(s).
  
  
  METHODS
  MOOD-HF is a prospective, randomised, double-blind, placebo-controlled, 2-armed, parallel-group multicenter trial investigating the effects of the serotonin re-uptake inhibitor (SSRI) escitalopram on morbidity and mortality (primary endpoint), severity of depression, anxiety, cognitive function, quality of life and health care expenditure in 700 patients with symptomatic systolic CHF and major depression diagnosed by structured clinical interview. All patients will receive optimised pharmacotherapy for CHF. Duration of follow-up, including close safety monitoring, is 12-24 months from randomisation.
  
  
  CONCLUSIONS
  MOOD-HF is the first prospective randomised controlled trial to assess the effects of antidepressant pharmacotherapy on hard somatic endpoints, the mechanism(s) of action of SSRI treatment, as well as safety in New York Heart Association functional class II-IV CHF patients. The results are expected to promote the development of evidence-based recommendations for managing depression in the context of CHF.
  
  
  BACKGROUND
  (ISRCTN.org). Identifier: ISRCTN33128015.
authors.affiliation: University of Würzburg, Department of Internal Medicine I/Center of Cardiovascular Medicine, Würzburg, Germany. angermann_c@klinik.uni-wuerzburg.de
authors.forename: Christiane E
authors.initials: CE
authors.lastname: Angermann
authors.forename: Götz
authors.initials: G
authors.lastname: Gelbrich
authors.forename: Stefan
authors.initials: S
authors.lastname: Störk
authors.forename: Andreas
authors.initials: A
authors.lastname: Fallgatter
authors.forename: Jürgen
authors.initials: J
authors.lastname: Deckert
authors.forename: Hermann
authors.initials: H
authors.lastname: Faller
authors.forename: Georg
authors.initials: G
authors.lastname: Ertl
mesh_terms: D000339:Affect / Q000187:drug effects*; D015283:Citalopram / Q000627:therapeutic use*; D003071:Cognition / Q000502:physiology; D003863:Depression / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D009017:Morbidity / Q000639:trends; D011446:Prospective Studies; D011788:Quality of Life; D012107:Research Design; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors